drugset

drugset / Trial / NCT05975983

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

NCT05975983 ↗

Phase 2 Recruiting 40 enrolled InSilico Medicine

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

Timeline

Start: 2024-02-08
Primary completion: 2026-02-28
Completion: 2026-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INS018_055	Small molecule	—	Oral

Indications